norfloxacin has been researched along with Bacteremia in 16 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
Bacteremia: The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a 5-year retrospective study to evaluate the effect of long-term administration of norfloxacin on the epidemiology of severe hospital-acquired infections in patients with advanced cirrhosis." | 5.30 | Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. ( Campillo, B; Dupeyron, C; Leluan, G; Mangeney, N; Richardet, JP, 1998) |
| "Oral norfloxacin is the standard of therapy in the prophylaxis of bacterial infections in cirrhotic patients with gastrointestinal hemorrhage." | 5.12 | Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. ( Arroyo, V; Durandez, R; Fernández, J; Gómez, C; Guarner, C; Navasa, M; Planas, R; Ruiz del Arbol, L; Serradilla, R, 2006) |
| " For primary prophylaxis, short-term antibiotic treatment (oral norfloxacin or ciprofloxacin) is indicated in cirrhotic patients (with or without ascites) admitted with gastrointestinal haemorrhage (variceal or non-variceal)." | 4.84 | [Bacterial infections in liver cirrhosis]. ( Farkas, A; Papp, M; Tornai, I; Udvardy, M, 2007) |
| "To determine the relative importance of temperate bacteriophage in the horizontal gene transfer of fitness and virulence determinants of Enterococcus faecalis, a panel of 47 bacteremia isolates were treated with the inducing agents mitomycin C, norfloxacin, and UV radiation." | 3.76 | Comparative genomics and transduction potential of Enterococcus faecalis temperate bacteriophages. ( Darby, AC; Edwards, C; Hall, N; Horsburgh, MJ; Kenny, JG; Shankar, J; Yasmin, A, 2010) |
| "We performed a 5-year retrospective study to evaluate the effect of long-term administration of norfloxacin on the epidemiology of severe hospital-acquired infections in patients with advanced cirrhosis." | 1.30 | Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. ( Campillo, B; Dupeyron, C; Leluan, G; Mangeney, N; Richardet, JP, 1998) |
| "Various neuropsychiatric syndromes in typhoid fever were seen in nine patients of multiple drug resistant (both in vitro and in vivo) Salmonella typhi infection of a total of 270 suspected cases in the last two years." | 1.28 | Neuropsychiatric manifestations of typhoid fever. ( Ali, G; Allaqaband, GQ; Aziz, A; Hussain, A; Kamili, MA; Koul, RL; Shah, MY, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 10 (62.50) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lontos, S | 1 |
| Shelton, E | 1 |
| Angus, PW | 1 |
| Vaughan, R | 1 |
| Roberts, SK | 1 |
| Gordon, A | 1 |
| Gow, PJ | 1 |
| Yasmin, A | 1 |
| Kenny, JG | 1 |
| Shankar, J | 1 |
| Darby, AC | 1 |
| Hall, N | 1 |
| Edwards, C | 1 |
| Horsburgh, MJ | 1 |
| Pantosti, A | 1 |
| Giuliano, M | 1 |
| Gentile, G | 1 |
| Cardines, R | 1 |
| Santilli, S | 1 |
| Mandelli, F | 1 |
| Martino, P | 1 |
| Fernández, J | 1 |
| Ruiz del Arbol, L | 1 |
| Gómez, C | 1 |
| Durandez, R | 1 |
| Serradilla, R | 1 |
| Guarner, C | 1 |
| Planas, R | 1 |
| Arroyo, V | 1 |
| Navasa, M | 1 |
| Papp, M | 1 |
| Farkas, A | 1 |
| Udvardy, M | 1 |
| Tornai, I | 1 |
| Carratalá, J | 1 |
| Fernández-Sevilla, A | 1 |
| Tubau, F | 1 |
| Callis, M | 1 |
| Gudiol, F | 1 |
| Broun, ER | 1 |
| Wheat, JL | 1 |
| Kneebone, PH | 1 |
| Sundblad, K | 1 |
| Hromas, RA | 1 |
| Tricot, G | 1 |
| Cogollos, R | 1 |
| Alós, JI | 1 |
| Gómez-Garcés, JL | 1 |
| Imperiale, TF | 1 |
| Esber, EJ | 1 |
| Bow, EJ | 1 |
| Mandell, LA | 1 |
| Louie, TJ | 1 |
| Feld, R | 1 |
| Palmer, M | 1 |
| Zee, B | 1 |
| Pater, J | 1 |
| Campillo, B | 1 |
| Dupeyron, C | 1 |
| Richardet, JP | 1 |
| Mangeney, N | 1 |
| Leluan, G | 1 |
| Martino, R | 1 |
| Subira, M | 1 |
| Altés, A | 1 |
| López, R | 1 |
| Sureda, A | 1 |
| Domingo-Albós, A | 1 |
| Pericas, R | 1 |
| Brunet, S | 1 |
| Rodríguez-Avial, I | 1 |
| Rodríguez-Avial, C | 1 |
| Picazo, JJ | 1 |
| D'Antonio, D | 1 |
| Iacone, A | 1 |
| Fioritoni, G | 1 |
| Betti, S | 1 |
| Dell'Isola, M | 1 |
| Quaglietta, AM | 1 |
| Accorsi, P | 1 |
| Pantalone, V | 1 |
| Recchia, A | 1 |
| Piergallini, A | 1 |
| Ali, G | 1 |
| Kamili, MA | 1 |
| Shah, MY | 1 |
| Koul, RL | 1 |
| Aziz, A | 1 |
| Hussain, A | 1 |
| Allaqaband, GQ | 1 |
| Cutajar, CL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding[NCT00838864] | Phase 4 | 79 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for norfloxacin and Bacteremia
| Article | Year |
|---|---|
[Bacterial infections in liver cirrhosis].
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ascites; | 2007 |
6 trials available for norfloxacin and Bacteremia
| Article | Year |
|---|---|
A randomized controlled study of trimethoprim-sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial I | 2014 |
Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Ba | 2006 |
Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation.
Topics: Acyclovir; Adult; Bacteremia; Bone Marrow Transplantation; Female; Fever; Fluconazole; Gram-Positive | 1994 |
Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Anti-Infective Agents; Antineoplastic Agents; Bacteremia; Colony Count, Microbial; Fema | 1996 |
Comparison of norfloxacin and pefloxacin in the prophylaxis of bacterial infection in neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bacteremia; Bacterial Infections; Female; Fever; Hum | 1992 |
Norfloxacin prophylaxis for endoscopic urological surgery.
Topics: Administration, Oral; Bacteremia; Bacteriuria; Endoscopy; Female; Humans; Kidney Calculi; Male; Norf | 1992 |
9 other studies available for norfloxacin and Bacteremia
| Article | Year |
|---|---|
Comparative genomics and transduction potential of Enterococcus faecalis temperate bacteriophages.
Topics: Anti-Bacterial Agents; Bacteremia; Bacteriophages; DNA Fingerprinting; DNA, Viral; Electrophoresis, | 2010 |
Anaerobic bacteremia in bone marrow recipients.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bacteremia; Bacteria, Anaerobic; Bone Marrow Tr | 1989 |
Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.
Topics: Adult; Aged; Aged, 80 and over; Bacteremia; Drug Resistance, Microbial; Escherichia coli Infections; | 1995 |
[Evolution of fluoroquinolone sensitivity in Staphylococcus aureus isolated from hemocultures in a general hospital].
Topics: Bacteremia; Blood; Ciprofloxacin; Cross Infection; Drug Resistance, Microbial; Hospitals, General; H | 1993 |
Preventing infection in cirrhotics with gastrointestinal hemorrhage.
Topics: Bacteremia; Bacterial Infections; Biometry; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; No | 1993 |
Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin.
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Ascitic Fluid; Bacteremia; Cross Infection; Dru | 1998 |
Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Bacteremia; Bacterial Infect | 1998 |
[In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Drug Resistance; Drug Resistance, M | 2001 |
Neuropsychiatric manifestations of typhoid fever.
Topics: Adolescent; Adult; Bacteremia; Drug Resistance, Microbial; Female; Humans; Male; Mental Disorders; N | 1992 |